Entero Therapeutics, INC 8-K filings

GridAI Technologies Corp. has entered into a material definitive agreement, providing a $2,000,000 secured convertible promissory note to Pronghorn Resources, LLC.

GridAI Technologies Corp. files an amendment to its Form 8-K to correct share and warrant allocations in a private placement raising approximately $8.5 million.

GridAI Technologies Corp. announced a private placement of common stock and warrants, raising approximately $8.5 million to fund general corporate purposes.

GridAI Technologies Corp. has entered into a Debt Settlement and Subscription Agreement to resolve a $1,032,315 debt obligation through an $800,000 cash payment and the issuance of 71,482 shares of common stock.

GridAI Technologies Corp. announced the closing of two private placement financings, raising approximately $2.54 million and $5.25 million respectively, to fund general corporate purposes.

GridAI Technologies Corp. has successfully regained compliance with Nasdaq's periodic financial reporting requirements after filing its 2025 annual report.

GridAI Technologies Corp. has received a Nasdaq non-compliance notice due to a delayed filing of its 2025 Annual Report on Form 10-K.

GridAI Technologies Corp. has received a formal demand for $1,014,675 following a default on its revolving loan agreement.

GridAI Technologies Corp. (formerly Entero Therapeutics, Inc.) filed an amendment to its Form 8-K, incorporating detailed risk factors, business overview, historical financial statements of GridAI Corp., and pro forma combined financial information.

GridAI Technologies Corp. has completed the rescission of its merger agreement with ImmunogenX, LLC, effectively divesting all interests in the former subsidiary.

GridAI Technologies Corp. has officially appointed Jason D. Sawyer as its Chief Executive Officer, formalizing his interim role and outlining a comprehensive two-year consulting agreement.

GridAI Technologies Corp., formerly Entero Therapeutics, Inc., announced a corporate name and ticker change to reflect its new AI and energy infrastructure focus, alongside the resignations of two directors, one citing governance concerns.

GridAI Corp stockholders have temporarily waived their right to appoint two directors to Entero Therapeutics, Inc.'s Board of Directors, pending shareholder approval.

Entero Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a share exchange agreement.

Entero Therapeutics, Inc. has entered into a Securities Purchase Agreement for a private placement, potentially raising up to $5 million through the sale of Promissory Notes and Common Stock Warrants.

Entero Therapeutics, Inc. has acquired 100% of GridAI Corp, a grid-edge AI platform, marking a strategic pivot into the high-growth AI energy-infrastructure market.

Entero Therapeutics, Inc. has formalized the appointment of Jason D. Sawyer as its Interim Chief Executive Officer through a consulting agreement with Access Alternative Group S.A.

Entero Therapeutics, Inc. announced the termination of its Interim CEO and Chairman, Richard Joel Paolone, and the immediate appointment of Jason D. Sawyer as the new Interim CEO.

Entero Therapeutics, Inc. announced a 1-for-3 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Entero Therapeutics, Inc. announced a $3.0 million private placement of pre-funded and common warrants, alongside the appointment of two new directors to its board, aimed at bolstering its financial position and corporate governance.

Entero Therapeutics, Inc. has amended its Rescission Agreement with ImmunogenX, LLC and its former shareholders, adding new representations and warranties, including an accredited investor requirement for shareholders.

Entero Therapeutics, Inc. announced it has regained compliance with Nasdaq Listing Rule 5620(a) regarding its annual meeting requirement, effectively closing the matter with the exchange.

Entero Therapeutics, Inc. announced that its stockholders approved all five proposals at the 2025 Annual Meeting, including the election of directors, a reverse stock split, and executive compensation.

Entero Therapeutics, Inc. has received an extension until October 8, 2025, from Nasdaq to regain compliance with the minimum stockholders' equity requirement, following a previous non-compliance notification.

Entero Therapeutics' subsidiary, ImmunogenX, LLC, settles debt with Mattress Liquidators Inc. and enters into an amended loan agreement for $2.43 million.

Entero Therapeutics received a notification from Nasdaq regarding non-compliance with minimum stockholders' equity requirements, potentially leading to delisting.

Entero Therapeutics has entered into a Rescission Agreement to unwind its previous merger with ImmunogenX, LLC, aiming to strengthen its balance sheet and refocus its strategy.

Entero Therapeutics, Inc. announces the resignation of its CFO, appointment of a new CFO, an extension to regain compliance with Nasdaq's minimum bid price requirement, and compliance with the Nasdaq Annual Meeting Rule.

Entero Therapeutics has appointed Richard Paolone as Interim CEO, replacing James Sapirstein, effective immediately.

Entero Therapeutics, Inc. has entered into a $2 million revolving loan agreement, resulting in a change of control with the lender appointing a majority of the board of directors.